Acrivon Therapeutics is a series c plus startup. 1 investor tracked on Brouky Intelligence. Status: possibledead. Data sourced from Brouky Intelligence.
About
Acrivon Therapeutics is a biopharmaceutical company leveraging its proprietary proteomics-based patient responder ID platform, Acrivon Predictive Precision (APPTM), to develop highly-selective oncology drugs.
Stage
series-c-plus
Investors
1
See full investor history, risk signals & comparable companies
Brouky tracks 15,000+ startups with funding rounds, risk analysis, and AI-powered investor matching.
Subscribe to Brouky